Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Chęć udziału w badaniu i podpisanie dokumentów zgody
- •Zaawansowany nowotwór litej postaci, dla którego pacjent otrzymał już wcześniej standardowe leczenie lub badanie kliniczne jest jego najlepszą opcją
- •Możliwość mierzenia nowotworu na badaniach obrazowych
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Dobre funkcjonowanie narządów wewnętrznych i szpiku kostnego
- •Gotowość do dostarczenia próbki tkanki guza (biopsji)
- •Dobry ogólny stan zdrowia (skala ECOG 0-1)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 130 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (60)
Research Site
Duarte, United States
Research Site
Irvine, United States
Research Site
La Jolla, United States
Research Site
Aurora, United States
Research Site
Louisville, United States
Research Site
Boston, United States
Research Site
Detroit, United States
Research Site
Columbus, United States
Research Site
Portland, United States
Research Site
Providence, United States
Research Site
Providence, United States
Research Site
Houston, United States
Research Site
Fairfax, United States
Research Site
Liverpool, Australia
Research Site
Melbourne, Australia
Research Site
Edmonton, Canada
Research Site
London, Canada
Research Site
Toronto, Canada
Research Site
Montreal, Canada
Research Site
Montreal, Canada
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Jinan, China
Research Site
Xi'an, China
Research Site
Zhengzhou, China
Research Site
Berlin, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Hanover, Germany
Research Site
Leipzig, Germany
Research Site
Mannheim, Germany
Research Site
Regensburg, Germany
Research Site
Haifa, Israel
Research Site
Ramat Gan, Israel
Research Site
Hidaka-shi, Japan
Research Site
Kashiwa, Japan
Research Site
Kōtoku, Japan
Research Site
Sunto-gun, Japan
Research Site
Tokyo, Japan
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Ankara, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Cambridge, United Kingdom
Research Site
Glasgow, Scotland, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Sutton, United Kingdom
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.